SEARCH

SEARCH BY CITATION

REFERENCES

  • Bondestam J, Mayranpaa MK, Ikegawa S, Marttinen E, Kroger H, Makitie O. 2007. Bone biopsy and densitometry findings in a child with Camurati–Engelmann disease. Clin Rheumatol 26: 17731777.
  • Bonnet N, Gadois C, McCloskey E, Lemineur G, Lespessailles E, Courteix D, Benhamou CL. 2007. Protective effect of beta blockers in postmenopausal women: Influence on fractures, bone density, micro and macroarchitecture. Bone 40: 12091216.
  • Byers PH. 2004. Determination of the molecular basis of Marfan syndrome: A growth industry. J Clin Invest 114: 161163.
  • Carter N, Duncan E, Wordsworth P. 2000. Bone mineral density in adults with Marfan syndrome. Rheumatology (Oxford) 39: 307309.
  • Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, Puffenberger EG, Hamosh A, Nanthakumar EJ, Curristin SM, et al. 1991. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352: 337339.
  • Edwards JR, Nyman JS, Lwin ST, Moore MM, Esparza J, O'Quinn EC, Hart AJ, Biswas S, Patil CA, Lonning S, et al. 2010. Inhibition of TGF-beta signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J Bone Miner Res 25: 24192426.
  • Ellis KJ, Shypailo RJ, Hardin DS, Perez MD, Motil KJ, Wong WW, Abrams SA. 2001. Z score prediction model for assessment of bone mineral content in pediatric diseases. J Bone Miner Res 16: 16581664.
  • Giampietro PF, Peterson M, Schneider R, Davis JG, Raggio C, Myers E, Burke SW, Boachie-Adjei O, Mueller CM. 2003. Assessment of bone mineral density in adults and children with Marfan syndrome. Osteoporos Int 14: 559563.
  • Giampietro PF, Peterson MG, Schneider R, Davis JG, Burke SW, Boachie-Adjei O, Mueller CM, Raggio CL. 2007. Bone mineral density determinations by dual-energy X-ray absorptiometry in the management of patients with Marfan syndrome—Some factors which affect the measurement. HSS J 3: 8992.
  • Gray JR, Bridges AB, Mole PA, Pringle T, Boxer M, Paterson CR. 1993. Osteoporosis and the Marfan syndrome. Postgrad Med J 69: 373375.
  • Gray JR, Bridges AB, Faed MJ, Pringle T, Baines P, Dean J, Boxer M. 1994. Ascertainment and severity of Marfan syndrome in a Scottish population. J Med Genet 31: 5154.
  • Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, et al. 2006. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312: 117121.
  • Holm TM, Habashi JP, Doyle JJ, Bedja D, Chen Y, van Erp C, Lindsay ME, Kim D, Schoenhoff F, Cohn RD, et al. 2011. Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 332: 358361.
  • Judge DP, Biery NJ, Keene DR, Geubtner J, Myers L, Huso DL, Sakai LY, Dietz HC. 2004. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest 114: 172181.
  • Karsenty G. 2001. Leptin controls bone formation through a hypothalamic relay. Recent Prog Horm Res 56: 401415.
  • Kohlmeier L, Gasner C, Marcus R. 1993. Bone mineral status of women with Marfan syndrome. Am J Med 95: 568572.
  • Kohlmeier L, Gasner C, Bachrach LK, Marcus R. 1995. The bone mineral status of patients with Marfan syndrome. J Bone Miner Res 10: 15501555.
  • Le Parc JM, Plantin P, Jondeau G, Goldschild M, Albert M, Boileau C. 1999. Bone mineral density in sixty adult patients with Marfan syndrome. Osteoporos Int 10: 475479.
  • Lee B, Godfrey M, Vitale E, Hori H, Mattei MG, Sarfarazi M, Tsipouras P, Ramirez F, Hollister DW. 1991. Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes. Nature 352: 330334.
  • Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, et al. 2010. The revised Ghent nosology for the Marfan syndrome. J Med Genet 47: 476485.
  • Maslen CL, Corson GM, Maddox BK, Glanville RW, Sakai LY. 1991. Partial sequence of a candidate gene for the Marfan syndrome. Nature 352: 334337.
  • Mohammad KS, Chen CG, Balooch G, Stebbins E, McKenna CR, Davis H, Niewolna M, Peng XH, Nguyen DH, Ionova-Martin SS, et al. 2009. Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS ONE 4: e5275.
  • Moura B, Tubach F, Sulpice M, Boileau C, Jondeau G, Muti C, Chevallier B, Ounnoughene Y, Le Parc JM. 2006. Bone mineral density in Marfan syndrome. A large case-control study. Joint Bone Spine 73: 733735.
  • Mundy GR, Bonewald LF. 1990. Role of TGF beta in bone remodeling. Ann N Y Acad Sci 593: 9197.
  • Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. 2003. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33: 407411.
  • Nistala H, Lee-Arteaga S, Carta L, Cook JR, Smaldone S, Siciliano G, Rifkin AN, Dietz HC, Rifkin DB, Ramirez F. 2010. Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. Hum Mol Genet 19: 47904798.
  • Pasco JA, Henry MJ, Nicholson GC, Schneider HG, Kotowicz MA. 2005. Beta-blockers reduce bone resorption marker in early postmenopausal women. Ann Hum Biol 32: 738745.
  • Reid IR, Gamble GD, Grey AB, Black DM, Ensrud KE, Browner WS, Bauer DC. 2005a. beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 20: 613618.
  • Reid IR, Lucas J, Wattie D, Horne A, Bolland M, Gamble GD, Davidson JS, Grey AB. 2005b. Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 90: 52125216.
  • Rejnmark L, Vestergaard P, Kassem M, Christoffersen BR, Kolthoff N, Brixen K, Mosekilde L. 2004. Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 75: 365372.
  • Rejnmark L, Vestergaard P, Mosekilde L. 2006. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: A nationwide case-control study. J Hypertens 24: 581589.
  • Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. 2002. Leptin regulates bone formation via the sympathetic nervous system. Cell 111: 305317.
  • Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, Zhao L, Nagy TR, Peng X, Hu J, et al. 2009. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 15: 757765.
  • Tobias JH, Dalzell N, Child AH. 1995. Assessment of bone mineral density in women with Marfan syndrome. Br J Rheumatol 34: 516519.
  • Turker S, Karatosun V, Gunal I. 2006. Beta-blockers increase bone mineral density. Clin Orthop Relat Res 443: 7374.
  • Zemel BS, Leonard MB, Kelly A, Lappe JM, Gilsanz V, Oberfield S, Mahboubi S, Shepherd JA, Hangartner TN, Frederick MM, et al. 2010. Height adjustment in assessing dual energy X-ray absorptiometry measurements of bone mass and density in children. J Clin Endocrinol Metab 95: 12651273.